04:31 PM EDT, 08/13/2026 (MT Newswires) -- Nektar Therapeutics ( NKTR ) reported a Q2 loss late Thursday of $1.23 per diluted share, narrowing from a loss of $2.95 a year earlier.
Analysts surveyed by FactSet expected a loss of $1.97.
Revenue for the three months ended June 30 was $10.1 million, down from $11.2 million a year earlier.
Analysts expected $10.4 million.